Back

GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition.

Chaudhary, N.; Choudhary, B. S.; Patra, S.; Malvankar, S.; Shivashankar, A.; Jog, E.; Kailaje, V. K.; Khanna, S.; Manna, S.; Sahoo, S.; R, S.; Jolly, M. K.; Dalal, S. N.; Verma, N.

2023-05-22 cancer biology
10.1101/2023.05.18.541287 bioRxiv
Show abstract

Frequent metastatic relapses in Triple-Negative Breast Cancer (TNBC) patients with residual disease is a clinical challenge, largely due to tumor heterogeneity and absence of strategies that target proliferating chemo-tolerant cells. Here, we longitudinally modeled cellular state transitions from dormant drug-tolerant persister (DTP) into proliferating drug-tolerant persister (PDTP) in cells representing all TNBC subtypes. Combining subcellular imaging with phenotypic and biochemical assays, we identified distinct and converged spectrums of alterations in TNBC-PDTPs. We show that PDTPs retain acquired resistance with increased invasion potential. Moreover, Basal-Like DTPs enter into a non-reversible mesenchymal state while luminal androgen receptor-positive gain partial-Epithelial-to-Mesenchymal Transition (EMT) with vimentin upregulation. PDTP state dwells on high autophagy with reduced glutathione and GPX4 levels, rendering it vulnerable to autophagy suppression and ferroptosis. Interestingly, we find that GPX4 negatively regulates EMT and autophagy in TNBC, and an inverse correlation of GPX4-VIM expression along with autophagy genes predicts survival in TNBC patients undergoing chemotherapy.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Translational Oncology
21 papers in training set
Top 0.1%
10.5%
2
Cell Death & Disease
126 papers in training set
Top 0.1%
9.7%
3
Frontiers in Oncology
103 papers in training set
Top 0.3%
7.8%
4
Cancers
213 papers in training set
Top 0.6%
7.8%
5
Molecular Oncology
55 papers in training set
Top 0.1%
6.7%
6
Cancer Letters
35 papers in training set
Top 0.1%
4.8%
7
Oncogene
85 papers in training set
Top 0.5%
4.0%
50% of probability mass above
8
Redox Biology
70 papers in training set
Top 0.3%
3.5%
9
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
3.4%
10
Cells
249 papers in training set
Top 2%
2.4%
11
Cell Death Discovery
58 papers in training set
Top 0.3%
2.4%
12
British Journal of Cancer
49 papers in training set
Top 0.6%
2.4%
13
Theranostics
37 papers in training set
Top 0.3%
2.1%
14
iScience
1154 papers in training set
Top 15%
1.9%
15
Cell Death & Differentiation
48 papers in training set
Top 0.6%
1.5%
16
Science Advances
1243 papers in training set
Top 22%
1.5%
17
Scientific Reports
3612 papers in training set
Top 62%
1.3%
18
International Journal of Cancer
49 papers in training set
Top 0.8%
1.3%
19
Cancer Research Communications
51 papers in training set
Top 1%
1.3%
20
eLife
5828 papers in training set
Top 58%
1.1%
21
Cancer Research
130 papers in training set
Top 2%
1.1%
22
International Journal of Molecular Sciences
494 papers in training set
Top 11%
1.1%
23
Neoplasia
23 papers in training set
Top 0.7%
1.0%
24
Nature Communications
5641 papers in training set
Top 54%
1.0%
25
Molecular Cancer Therapeutics
40 papers in training set
Top 0.8%
1.0%
26
Cell Communication and Signaling
51 papers in training set
Top 1%
1.0%
27
PNAS Nexus
159 papers in training set
Top 3%
0.8%
28
Communications Biology
993 papers in training set
Top 31%
0.8%
29
PLOS ONE
5266 papers in training set
Top 62%
0.8%
30
Cell Reports
1498 papers in training set
Top 27%
0.8%